Related Experiment Videos
Comparative tolerability of oral 5-HT1B/1D agonists.
1EBD Group Inc, Carlsbad, California 92009, USA.
Headache
|August 12, 2000
Summary
Triptans (5-HT1B/1D agonists) vary in tolerability, with dose, Cmax, and lipophilicity correlating for most, except eletriptan. Adverse event frequency cannot be predicted by these factors, suggesting non-5-HT1B/1D receptor mechanisms.
Area of Science:
- Pharmacology
- Clinical Therapeutics
- Drug Development
Background:
- 5-HT1B/1D agonists, commonly known as triptans, are widely used for migraine treatment.
- Understanding their tolerability profiles is crucial for patient management and drug selection.
- Factors influencing triptan adverse events require further investigation.
Purpose of the Study:
- To compare the relative tolerability of various 5-HT1B/1D agonists.
- To explore the relationship between systemic exposure (dose, Cmax), lipophilicity (LogD), and clinical tolerability.
- To identify predictors of adverse event frequencies for triptans.
Main Methods:
- Post hoc analysis correlating absolute dose, Cmax, and LogDpH7.4 with adverse event frequencies.
- Adverse events (all, neurological, dizziness/somnolence/drowsiness) were adjusted for placebo frequencies.
- Data from multiple 5-HT1B/1D agonists were analyzed.
Main Results:
- A dose-response relationship for adverse events was observed for most triptans.
- Rank order of adverse event frequency: naratriptan < sumatriptan = rizatriptan < zolmitriptan.
- Correlations found between absolute dose, Cmax, and LogD for most triptans (except eletriptan), but these did not predict adverse event frequencies.
Conclusions:
- Triptans exhibit distinct tolerability profiles.
- Effectiveness, dose, and lipophilicity are interrelated for these 5-HT1B/1D agonists, excluding eletriptan.
- Adverse effects are unlikely mediated by 5-HT1B/1D receptors; individual clinical study is essential.